Timing Tech Transfer With Complex Raw Materials

Tech transfer complexity depends on product maturity, but don't assume a straightforward experience just because you have market approval and a commercial product. In fact, the risk is often greater. When outsourcing drug product manufacturing to scale up for clinical production or expanding capacity for a commercial product, it's best not to guess, Yan Zhi says in this segment of Cell & Gene Live "Viability On The Line."

While still highly complex, early-phase tech transfers usually offer more flexibility, and there's breathing room to work out the kinks before commercial launch.